Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 4,646

Document Document Title
WO/2009/064604A1
A compound for use as an antioxidant having the formula (I): R1 and R2 together with the carbon atoms to which they are bonded are joined together to form a C3-C30 ring. The C3-C30 ring may be substituted with one or more substituents or...  
WO/2009/063061A2
The present invention relates to compounds defined by formula (I), wherein the groups R1 to R3, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hyd...  
WO/2009/060654A1
Disclosed is an anthrapyridone compound represented by the formula (1) below or a salt thereof, which is a magenta dye (compound) having high solubility in water, and hue and clarity suitable for inkjet recording. This magenta dye (compo...  
WO/2009/056520A1
The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein R1 is hydrogen or C1-4alkyl; R2 is a group A or W, wherein A is formula (IA) wherein p is 0, 1, 2...  
WO/2009/038958A1
An improved method for producing apomorphine and derivatives thereof is provided. The method is a convenient 'one-pot' process, comprising the conversion of codeine into apomorphine without isolating the apocodeine intermediate. Use of w...  
WO/2009/034216A1
The invention relates to the use of compounds of general formulae (1), (2), (3), (4) and (5) as selective inhibitors of monoamino oxidase, especially inhibitors of MAO-A, for preparing a medicament for the treatment of depression disorders.  
WO/2009/026935A1
The present invention relates to novel catecholamine derivatives of Formula (I), to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.  
WO/2009/027952A1
A benzoterrylene of Formula (I) wherein at least one of the pairs R4-R5, R6-R7, R10-R11, and R12-R13 is a ring structure selected from the group consisting of Formulas (A), (B), and (C) wherein Y1 through Y4 are each independently select...  
WO/2009/027294A1
The present invention relates to novel compounds of formula (I)', pharmaceutically acceptable salts, prodrugs or solvates thereof wherein R1 is hydrogen or C1-4 alkyl; R2 is an α or β naphthyl group, optionally substituted by 1 or 2 gr...  
WO/2009/028563A1
Disclosed is a process for producing a cis-3-substituted-3-azabicyclo[3.2.1]octan-8-ol derivative, which is characterized by isomerizing a trans-3-substituted-3-azabicyclo[3.2.1]octan-8-ol derivative or a mixture of a trans-3-substituted...  
WO/2009/027295A1
The present invention relates to compounds of formula (I), processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) a...  
WO/2009/023567A1
Compounds of formulas (A) and (B) are disclosed. The compounds of this invention are useful for ameliorating the side effects of therapeutic opiates.  
WO/2009/019901A1
It is intended to provide a nucleic acid derivative into which a given compound has been introduced in a manner specific to a base of a nucleic acid. A DNA, an RNA or a nucleic acid molecular weight marker, characterized in that a given ...  
WO/2009/013258A1
The invention relates to compounds of general formula (I) and to the use thereof as active materials in solar cells and photodetectors. The variables in formula (I) are defined in the specifications.The formula (I) also has the following...  
WO/2009/007443A2
A new class of ligands derived from benzo[h]quinoline are described and these ligands are used to prepare several novel transition metal complexes. The complexes are preferably of the group VIII transition metals iron, ruthenium or osmiu...  
WO/2008/156142A1
It is intended to provide a novel compound which has AT2 receptor agonism and is capable of being expected as a pharmaceutical and to provide a therapeutic or preventive method for various diseases. A novel malonic acid sulfonamide deriv...  
WO/2008/147314A1
Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith  
WO/2008/147544A1
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In...  
WO/2008/147547A1
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In...  
WO/2008/144394A2
Compounds of formula (I) are disclosed. In these compounds (1) or (2) is a heterocyclic ring. The compounds are useful as analgesics, anti-pruritics, anti-diarrheal agents, anticonvulsants, antitussives, anorexics/antiobesity agents and ...  
WO/2008/143263A1
It is intended to provide a compound useful as an N-type Ca2+ channel blocker. As a result of intensive studies of compounds having an action of blocking the N-type Ca2+ channel, the present inventors found that a tetrahydroisoquinoline ...  
WO/2008/129007A1
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts, solvates, stereoisomers thereof, formula (I), R1 may be C1-C4 alkyl, aryl or heteroaryl, which may be substituted by one or more: halogen,...  
WO/2008/125008A1
The invention provides a cyclohepta[b]pyridine compounddescribed as formula I and pharmaceutically acceptable salts thereof. The invention also provides the method for preparation of these cyclohepta[b]pyridine compounds as well as the u...  
WO/2008/121817A2
The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selectins. Metho...  
WO/2008/119797A1
Disclosed are dinaphthoquaterrylene derivatives of general formula (I), wherein the variables have the following meaning: X: both represent COOM or are combined into a radical of formula (x1), (x2), or (x3); Y: one of the two radicals re...  
WO/2008/121686A1
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide, ketone, and ester compounds prepared from certain azabicycloalkane carboxylic acids. The r...  
WO2008007262B1
The bisnaphthalimidopropyl derivatives with anti-parasitic and anti-cancer activity. Bisnaphthalimidopropyl derivatives (A) BNIPPut, BNIPDapen, BNIPDhex, BNIPDahep, BNIPDaoct, BNIPDanon, BNTPDadec, BNIPDadod, BNPDpta, BNIPDeta were synth...  
WO/2008/111767A1
The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's dis...  
WO/2008/109007A1
Bridged phenanthridine compounds having the structure of formula I or of formula II are provided. These compounds are useful as cannabinoid receptor ligands and can be prepared as pharmaceutical compositions for the prophylaxis or treatm...  
WO/2008/106104A2
The present invention generally relates to environment-sensitive fluorophores, including environment-sensitive fluorophores for reporting protein/protein and peptide/protein interactions. In one aspect, the present invention is directed ...  
WO/2008/096739A1
Disclosed is a composition containing a compound having a benzimidazole ring structure and a phosphorescent compound.  
WO/2008/093614A1
Disclosed is a hepatitis C virus (HCV) inhibitor which can affect the replication of HCV or the translation of a HCV protein. Specifically disclosed is an HCV inhibitor comprising a compound selected from compounds represented by the for...  
WO/2008/093737A1
Disclosed is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a renin inhibitor. (I) wherein R1a represents a hydrogen atom, a C1-6 alkyl group which may be substituted, or the l...  
WO/2008/093881A1
Disclosed is a method for producing a nitroxyl radical derivative which can cause the substitution at position-2 and position-6 in a TEMPO compound readily and has high versatility. Also disclosed is a method for producing a nitroxyl rad...  
WO/2008/086678A2
Levo-phencynonate and its nontoxic pharmaceutically acceptable salt having neuroprotective effect, the composition comprising these compounds as active components, and the use as neuroprotective agents. The structure of levo-phencynonate...  
WO/2008/087936A1
Disclosed is a compound having an activity of selectively binding to a glucocorticoid receptor (GR) and having less activity on other nuclear receptors such as a progesterone receptor (PR) or a mineralocorticoid receptor (MR). Specifical...  
WO/2008/084496A1
The present invention relates to novel substituted 1H-benz[de]isoquinoline-1,3-diones. This invention particularly relates to novel substituted 1H-benz[de]isoquinoline-1,3-diones particularly N-[2-(Chloroethyl)]- and N-[3-(Chloropropyl)]...  
WO/2008/080290A1
Levo-nor-phencynonate and its nontoxic pharmaceutically acceptable salt as selective M4 receptor antagonists, the composition comprising these compounds as active components, and their uses in manufacture of medicaments for treating moto...  
WO/2008/082715A2
Peptidyl sensors comprise a metal-binding peptide and one or two kinase recognition sequences with a hydroxyamino acid that can be phosphorylated in the presence of a kinase.  
WO/2008/078824A1
There are provided a novel benzofluoranthene compound and an organic light-emitting device which uses the benzofluoranthene compound, gives a blue emission hue with extremely good purity, and has an optical output with a high efficiency,...  
WO/2008/076427A2
Compounds of Formula (I) and Formula (II) are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula(I) and Formula (II) have the following structures, where the definitions of the variables are provided herein.  
WO/2008/072850A1
The present invention relates to a novel triazine derivative or a pharmaceutically acceptable salt thereof, and an Acetyl-CoA Carboxylase (ACC) comprising same as an active ingredient. The triazine derivative of the present invention eff...  
WO/2008/073613A2
The subject invention pertains to methods for solid-state synthesis of imides and imines using co-crystals. The co-crystal formers utilized are substrates of condensation reactions and co-crystals can be obtained in high yield via method...  
WO/2008/069322A1
Disclosed is a light-emitting device capable of emitting red light with high luminance and high efficiency, while having excellent durability. Also disclosed is a metal coordination compound having a partial structure represented by the ...  
WO/2008/069242A1
Disclosed is a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. (1) wherein R1 represents a halogen atom or the like, and R2 represents a hydrogen atom or the like, or R1 and R2 may together form a 5...  
WO/2008/066024A1
Disclosed is a novel anthrapyridone compound represented by the formula (1) below or a salt thereof. The anthrapyridone compound or a salt thereof enables to provide a magenta dye having a hue with high clarity suitable for inkjet record...  
WO/2008/059513A2
Disclosed herein in the embodiments of the present invention are the compounds suitable as modulators of HDL having general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmac...  
WO/2008/058342A1
The present application discloses the Tv-stp-1 serine/threonine phosphatase gene from Trichostrongylus vitrinus, and compounds that are useful as invertebrate control agents.  
WO/2008/056059A2
The present invention pertains to the field of pharmacy, mainly to that of cytoprotection. The invention relates to a family of new chemical compounds, i.e. the 4- azacholest-4-ene N-oxide and certain derivatives thereof, to methods for ...  
WO/2008/055068A2
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein (B), Q, J, L and Z are as defined in the specification.  

Matches 601 - 650 out of 4,646